CovEMERALD: Assessing the feasibility and preliminary effectiveness of remotely delivered Eye Movement Desensitisation and Reprocessing following Covid-19 related critical illness: A structured summary of a study protocol for a randomised controlled trial.
Adult
Anxiety
/ etiology
Betacoronavirus
COVID-19
Coronavirus Infections
/ diagnosis
Critical Illness
/ psychology
Depression
/ etiology
Eye Movement Desensitization Reprocessing
/ methods
Feasibility Studies
Female
Home Care Services, Hospital-Based
Humans
Internet-Based Intervention
Male
Pandemics
Pneumonia, Viral
/ diagnosis
Psychological Techniques
Quality of Life
Randomized Controlled Trials as Topic
SARS-CoV-2
Stress Disorders, Post-Traumatic
/ etiology
Anxiety
COVID-19
EMDR
Eye-movement desensitisation and reprocessing
Intensive Care
PTSD
Protocol
Psychology
Randomised controlled trial
Survivors
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
17 Nov 2020
17 Nov 2020
Historique:
received:
25
09
2020
accepted:
14
10
2020
entrez:
18
11
2020
pubmed:
19
11
2020
medline:
24
11
2020
Statut:
epublish
Résumé
Primary Objective: To determine the feasibility of delivering a protocolised, remote, online, Eye Movement Desensitisation and Reprocessing (EMDR) intervention, within 12-weeks of hospital discharge, for adult survivors of Covid-19 related critical illness. Secondary objectives: To investigate whether remotely delivered EMDR can improve psychological outcome following Covid-19 related critical illness, specifically Post-Traumatic Stress Disorder (PTSD), anxiety and depression. This is a single centre, randomised controlled cohort feasibility trial. Participants will be recruited following discharge from the Intensive Care Unit at University Hospital Southampton, United Kingdom. Eligible patients will have received mechanical ventilation for a minimum of 24 hours, tested Covid-19 positive by polymerase chain reaction, will be over the age of 18 years and have the capacity to provide informed consent. Patients will be excluded if they have pre-existing cognitive impairment, pre-existing psychotic diagnosis or are not expected to survive post-hospital discharge. Group one: patients in the control arm will receive their standard package of prescribed care, following discharge home from hospital. If they experience any adverse physical or psychological health-conditions, they will access care through the usual available channels. Group two: patients randomly allocated to the intervention arm will receive their standard package of prescribed care, following discharge home from hospital. In addition, they will be referred to the Intensive Psychological Therapies Service in Poole, United Kingdom. They will receive an online appointment within 12-weeks of discharge home from hospital. They will receive a maximum of eight, weekly sessions of EMDR, delivered by a trained psychological therapist, following the Recent Traumatic Episode Protocol (R-TEP). Appendices 1 and 2 of the attached trial protocol contain a detailed description of the R-TEP intervention, written in accordance with the Template for Intervention Description and Replication (TIDieR) checklist and guide. The primary outcome from this trial will be feasibility. Feasibility will be determined by recruitment rates, expressed as a percentage of eligible patients approached, completion of the EMDR intervention, completion of final assessment at 6-months, incidence of attributable adverse events and protocol adherence by the psychological therapists. Secondary, exploratory outcomes will be assessed by comparison between the control and intervention groups at 6-months post-hospital discharge. Psychometric evaluation will consist of the PTSD Checklist-Civilian Version and Hospital Anxiety and Depression Scale. In addition, we will assess health-related quality of life using the EQ5D-5L, physical activity using wrist worn activity monitors and nutritional state using the Council of Nutrition Appetite Questionnaire. Consenting participants will be randomly allocated to intervention or usual care using an internet-based system (ALEA This is a feasibility study, the results of which will be used to power a definitive study if appropriate. We anticipate a 25% mortality /loss to follow-up. A total of 26 patients will be recruited to this study, 13 patients in each arm. CovEMERALD opened to recruitment on 23
Identifiants
pubmed: 33203440
doi: 10.1186/s13063-020-04805-1
pii: 10.1186/s13063-020-04805-1
pmc: PMC7670988
doi:
Banques de données
ClinicalTrials.gov
['NCT04455360']
Types de publication
Clinical Trial Protocol
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
929Subventions
Organisme : Department of Health
ID : NIHR300405
Pays : United Kingdom
Organisme : Research Trainees Coordinating Centre
ID : nihr300405